Ascendis Pharma A/S (ASND)
122.87
-1.17
(-0.94%)
USD |
NASDAQ |
May 16, 16:00
122.87
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Free Cash Flow: -460.07M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -460.07M |
| December 31, 2023 | -508.61M |
| September 30, 2023 | -635.97M |
| June 30, 2023 | -587.18M |
| March 31, 2023 | -546.09M |
| December 31, 2022 | -538.04M |
| September 30, 2022 | -520.28M |
| June 30, 2022 | -555.66M |
| March 31, 2022 | -570.03M |
| December 31, 2021 | -522.83M |
| September 30, 2021 | -473.68M |
| June 30, 2021 | -433.68M |
| March 31, 2021 | -358.09M |
| December 31, 2020 | -334.73M |
| September 30, 2020 | -288.38M |
| June 30, 2020 | -272.67M |
| March 31, 2020 | -211.27M |
| December 31, 2019 | -202.74M |
| September 30, 2019 | -190.50M |
| Date | Value |
|---|---|
| June 30, 2019 | -176.74M |
| March 31, 2019 | -193.70M |
| December 31, 2018 | -167.03M |
| September 30, 2018 | -146.42M |
| June 30, 2018 | -126.83M |
| March 31, 2018 | -130.99M |
| December 31, 2017 | -108.77M |
| September 30, 2017 | -102.37M |
| June 30, 2017 | -85.97M |
| March 31, 2017 | -73.81M |
| December 31, 2016 | -67.35M |
| September 30, 2016 | -60.64M |
| June 30, 2016 | -57.19M |
| March 31, 2016 | -57.81M |
| December 31, 2015 | -49.39M |
| September 30, 2015 | -48.24M |
| June 30, 2015 | -38.41M |
| March 31, 2015 | -29.52M |
| December 31, 2014 | -25.01M |
Free Cash Flow Range, Past 5 Years
-635.97M
Minimum
Sep 2023
-176.74M
Maximum
Jun 2019
-419.36M
Average
-466.87M
Median
Free Cash Flow Benchmarks
| Evaxion Biotech AS | -- |
| Biodexa Pharmaceuticals Plc | -8.842M |
| Autolus Therapeutics PLC | -156.57M |
| NuCana PLC | -33.49M |
| TC BioPharm (Holdings) PLC | -13.42M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -110.34M |
| Cash from Investing (Quarterly) | 7.772M |
| Cash from Financing (Quarterly) | 20.01M |
| Free Cash Flow Per Share (Quarterly) | -1.944 |
| Free Cash Flow to Equity (Quarterly) | -230.06M |
| Free Cash Flow to Firm (Quarterly) | -29.07M |
| Free Cash Flow Yield | -6.63% |